提醒成功
微信/QQ登录
搜索
首页
| 产品规范 | |
|---|---|
| Type | In Vivo - Reseach Grade Antibody |
| Host | CHO cells |
| catalog# | B00039 |
| Application | Flow cytometry, animal model study |
| Aliases | cluster of differentiation-22, SIGLEC-2, SIGLEC2 |
| Size/Concentration | 1mg/5mg/20mg |
| Isotype | Human IgG1 kappa |
| Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Human CD22 |
| Formulation | PBS, pH 7.4 |
Description |
|---|
Epratuzumab Biosimilar uses the same protein sequences as the therapeutic antibody epratuzumab. Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus. Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. It binds with high specificity to normal B-cells and B-cell tumors at the third Ig-like domain of CD22. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). |
Epratuzumab Biosimilar, CD22 Monoclonal Antibody B00039
规格：
- 1mg
- 5mg
- 20mg
数量：
-
+
说明书：
¥3250
-
分享
-
咨询
-
收藏
联系方式
CONTACT-
联系电话:
0731-88388785 -
公司邮箱:
sales@promab.cn -
公司地址:
湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼
官方微信
产品中心
Product技术服务
service客户留言
message